1. Israel Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Sisram Medical Ltd.

Sisram Medical Ltd.

1.74
HKD
-0.11
(-6.22%)
1.97BMarket Cap
Mar 24Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.25
0.27
0.29
0.48
0.35
0.39
0.37
0.65
0.76
0.77
0.75
0.78
- -
Basic EPS, GAAP
0.01
0.02
0.02
0.04
0.05
0.05
0.03
0.07
0.09
0.07
0.05
0.04
- -
Free Cash Flow per Basic Share
0.05
0.04
0.04
0.05
0.03
0.04
0.04
0.06
-0.09
0.08
0.03
0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
0.01
0.01
0.01
0.02
0.02
0.02
0.02
- -
Book Value per Share
0.06
0.08
0.1
0.66
0.71
0.74
0.75
0.86
0.92
0.97
0.99
1.02
1.02
Tangible Book Value per Share
-0.4
-0.37
-0.33
0.27
0.33
0.35
0.38
0.51
0.59
0.4
0.42
0.46
0.46
Basic Weighted Avg Shares
404
404
404
285
442
442
442
453
466
467
468
468
468
Sales/Revenue/Turnover
101
110
118
137
154
174
162
294
354
359
349
365
- -
Operating Margin (%)
17.94
18.64
17.39
15.25
15.91
15.03
12.58
17.18
15.64
11.71
10.21
8.91
- -
Depreciation Expense
5
6
6
6
6
10
10
12
12
14
17
17
- -
Net Income, GAAP
6
8
8
11
22
21
13
31
40
31
25
19
- -
Effective Tax Rate (%)
28.08
21.36
28.32
30.16
4.18
11.69
11.9
21.96
9.41
11.4
11.6
12.42
- -
Profit Margin (%)
5.87
7.08
6.82
8.07
14.18
11.98
8.23
10.62
11.33
8.77
7.2
5.2
- -
Working Capital
50
44
48
132
151
157
150
214
170
169
154
170
170
LT Debt
191
185
37
7
- -
7
33
31
33
36
34
35
35
Total Equity
25
33
40
293
314
326
332
404
432
470
485
504
504
Return on Invested Capital (%)
- -
7.09
8.91
7.2
7.57
7.05
5.17
9.67
10.88
7.5
6.68
5.22
- -
Return on Capital (%)
- -
5.64
7.7
7.33
7.33
6.2
3.66
7.75
9.11
6.46
4.54
2.93
- -
Return on Common Equity (%)
- -
27.1
22.06
6.63
7.19
6.5
4.06
8.51
9.64
7.13
5.48
4.03
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
9
10
16
LT Borrowings
- -
- -
- -
LT Finance Leases
34
37
35
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
468
468
468
Market Capitalization
228
260
253

Working Capital

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
249
256
276
Cash, Cash Equivalents & STI
72
62
71
Accounts Receivable, Net
81
88
93
Inventories
81
88
93
Total Current Liabilities
95
97
106
Payables & Accruals
- -
- -
- -
ST Debt
9
10
16
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
70.53%
8.9%
3.9%
Free Cash Flow
-44.66%
-92.17%
-54.37%
Net Income, GAAP
19.38%
19.31%
-24.32%
Sales/Revenue/Turnover
14.67%
21.04%
4.65%
Total Cash Common Dividend
- -
14.34%
-20.23%

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
359
2024
- -
- -
349
2025
- -
- -
365

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.07
2024
- -
- -
0.05
2025
- -
- -
0.04

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
0.02
2025
- -
- -
0.02

Company Description

Company Profile APIChatGPT
CEO
Jiahong Li
Full Time Employees
1,047
Sector
Health technology
Industry
Medical specialties
Address
Ofek Building 15 Caesarea HA Israel 3079895
IPO Date
Sep 19, 2017
Website
sisram-medical.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Sisram Medical Ltd (1696.HK) is an Israel-based global consumer wellness group that designs, develops, manufactures, markets and sells energy-based medical aesthetic devices, dental equipment, injectables, home-use devices and cosmeceuticals; its core offerings include the Alma brand's energy-based solutions for hair removal (Soprano Titanium), skin rejuvenation, acne and scar treatment, body and face contouring, pigmentation and vascular lesion therapies, skin resurfacing, cellulite reduction, feminine health and aesthetic dentistry via the Copulla digital platform; LMNT personal care products; and an expanding injectables portfolio featuring Revanesse dermal fillers, Profhilo hyaluronic acid injectables, Hallura HA-bio-stimulator combinations and DAXXIFY botulinum toxin. Founded in 2013 through the acquisition of Alma Lasers and headquartered at Ofek 15 Building, 18 HaHarash Street, Caesarea Industrial Park, Israel, the company operates direct sales offices and distribution channels across more than 100 countries, with key regions encompassing Europe, North America, Asia Pacific (including China, Japan, Hong Kong, Thailand and Australia), Latin America and the Middle East & Africa; it is majority-owned by Fosun Pharma. Recent developments include the global launch of the Alma Harmony multi-modal anti-aging platform and Alma IQ intelligent skin analysis tool in 2024-2025, NMPA approval and planned mainland China commercialization of DAXXIFY in 2025, partnerships with Prollenium for Revanesse UK launch, Hallura for exclusive distribution and Profhilo approvals in Hainan and Thailand, establishment of direct sales offices in Thailand and China via PhotonMed acquisition integration, European MDR certification for accelerated product launches, and the November 2025 debut of Universkin by Alma AI-assisted personalized skincare in Hong Kong, driving double-digit growth in injectables (218% in H1 2025) and direct sales contribution to 87% of revenue.